Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy

Journal:
Proceedings of the National Academy of Sciences of the United States of America
Published:
DOI:
10.1073/pnas.2508762123
Affiliations:
3
Authors:
21
Go to article
Institutions Authors Share
Novartis Biomedical Research, Switzerland
12.000000
12.000000
 0.57
Novartis Biomedical Research, United States of America (USA)
8.000000
 0.38
Novartis, Switzerland
1.000000
 0.05
Interested in Oncology and Carcinogenesis?